Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Galapagos NV

Biopharma SG&A Trends: Amphastar vs. Galapagos

__timestampAmphastar Pharmaceuticals, Inc.Galapagos NV
Wednesday, January 1, 2014403730009079000
Thursday, January 1, 20154697400020309000
Friday, January 1, 20164729800016945000
Sunday, January 1, 20175091800020559000
Monday, January 1, 20185804400029641000
Tuesday, January 1, 20196310900088258000
Wednesday, January 1, 202065157000162170000
Friday, January 1, 202168920000167218000
Saturday, January 1, 202266592000239528000
Sunday, January 1, 20238039300094252000
Loading chart...

Infusing magic into the data realm

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the ever-evolving landscape of biopharmaceuticals, cost management remains a pivotal factor for success. Amphastar Pharmaceuticals, Inc. and Galapagos NV, two prominent players, have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amphastar's SG&A expenses grew steadily, peaking at approximately 80 million USD in 2023, marking a 99% increase from 2014. In contrast, Galapagos NV experienced a more volatile trajectory, with expenses surging by over 2500% from 2014 to 2022, before a notable decline in 2023. This divergence highlights the strategic differences in cost management and operational scaling between the two companies. As the industry continues to innovate, understanding these financial dynamics offers valuable insights into the strategic priorities and market positioning of these biopharma leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025